EMTRICITABINE/TENOFOVIR DISOPROXIL TEVA 200 mg/245 mg, film-coated tablet 30 tablets, CIP 3400930266380
Active ingredients: Emtricitabine, Tenofovir disoproxil phosphate, Tenofovir disoproxil
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tablets, CIP 3400930266380orale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- EMTRICITABINE/TENOFOVIR DISOPROXIL TEVA 200 mg/245 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) de 30 comprimé(s) avec fermeture de sécurité enfant et fermé par un bouchon (PP) et 3 g de déshydratant
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 21 Dec 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62966914CIP73026638CIP133400930266380Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TÉNOFOVIR DISOPROXILcomprimé | 245 mg · un comprimé | FT |
| EMTRICITABINEcomprimé | 200 mg · un comprimé | SA |
| PHOSPHATE DE TÉNOFOVIR DISOPROXILcomprimé | 291,22 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.